Skip to main content

Avid Bioservices, Inc. (CDMO)

NASDAQ: CDMO · IEX Real-Time Price · USD
25.79 0.97 (3.91%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap1.60B
Revenue (ttm)101.23M
Net Income (ttm)5.61M
Shares Out61.14M
EPS (ttm)0.11
PE Ratio241.03
Forward PE99.01
Dividendn/a
Ex-Dividend Daten/a
Volume868,878
Open25.13
Previous Close24.82
Day's Range24.76 - 26.47
52-Week Range6.99 - 28.36
Beta2.24
AnalystsStrong Buy
Price Target28.25 (+9.5%)
Est. Earnings DateDec 1, 2021

About CDMO

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides var...

IndustryBiotechnology
Founded1981
CEORichard Hancock
Employees252
Stock ExchangeNASDAQ
Ticker SymbolCDMO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CDMO stock is "Strong Buy." The 12-month stock price forecast is 28.25, which is an increase of 9.54% from the latest price.

Price Target
$28.25
(9.54% upside)
Analyst Consensus: Strong Buy

News

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market

1 day ago - GlobeNewsWire

Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks' Debut on Sept. 17

Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.

Other symbols:BNTX
1 month ago - InvestorPlace

Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...

1 month ago - Zacks Investment Research

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D.

Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry E...

3 months ago - GlobeNewsWire

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Develop...

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --

3 months ago - GlobeNewsWire

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on J...

TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives ...

3 months ago - GlobeNewsWire

Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

7 A-Rated Biotech Stocks to Buy Now

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inves...

Other symbols:BNGOBNTXMRNAVTGN
4 months ago - InvestorPlace

Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?

Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 months ago - Zacks Investment Research

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) ...

4 months ago - GlobeNewsWire

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...

5 months ago - InvestorPlace

Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

5 months ago - Zacks Investment Research

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to impr...

6 months ago - GlobeNewsWire

5 Stocks to Buy on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

Other symbols:ASYSAYTUIBKRONCT
6 months ago - Zacks Investment Research

Find Strong Stocks to Start Q2 with New Analyst Coverage

Find Strong Stocks to Start Q2 with New Analyst Coverage

Other symbols:IBKRMP
6 months ago - Zacks Investment Research

These 5 Stocks Are Safe Bets Courtesy of New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Interactive Brokers (IBKR), Avid (CDMO), Amtech (ASYS) and GAIA

Other symbols:ASYSGAIAIBKRUFPI
6 months ago - Zacks Investment Research

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...

6 months ago - GlobeNewsWire

Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?

Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon

7 months ago - Zacks Investment Research

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...

7 months ago - GlobeNewsWire

Avid Bioservices (CDMO) Surpasses Q3 Earnings and Revenue Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 150.00% and 9.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes

TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...

7 months ago - GlobeNewsWire

Avid Bioservices: Q3 Earnings Insights

Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 116.67% over the past year to $0.01, which bea...

7 months ago - Benzinga

Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments

-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- S igned $74 Million in New Orders to End the Quarter with a Backlog of $120 Million --

7 months ago - GlobeNewsWire

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...

7 months ago - GlobeNewsWire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...

7 months ago - GlobeNewsWire